Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

3 weeks ago

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate…

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

3 weeks ago

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol…

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

3 weeks ago

Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option…

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

3 weeks ago

TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the “Company”) (NASDAQ: SCNX), a specialty pharma company with…

Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference

3 weeks ago

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled…

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

3 weeks ago

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and…

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

3 weeks ago

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review…

Transpire Bio Achieves Important Corporate Milestone with Completion of First Human Subject Study in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program

3 weeks ago

WESTON, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled medicines,…

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

3 weeks ago

- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer -…

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

3 weeks ago

SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in…